Autolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC grew its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 27.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,300,000 shares of the company's stock after purchasing an additional 925,000 shares during the period. Autolus Therapeutics makes up approximately 1.7% of Affinity Asset Advisors LLC's portfolio, making the stock its 15th biggest holding. Affinity Asset Advisors LLC owned about 1.62% of Autolus Therapeutics worth $14,964,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. ProShare Advisors LLC acquired a new position in Autolus Therapeutics in the 2nd quarter valued at $43,000. Bayesian Capital Management LP acquired a new position in shares of Autolus Therapeutics during the first quarter worth about $100,000. Daiwa Securities Group Inc. raised its holdings in Autolus Therapeutics by 2,659.7% during the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in Autolus Therapeutics in the first quarter valued at about $108,000. Finally, SG Americas Securities LLC purchased a new stake in Autolus Therapeutics in the 1st quarter valued at approximately $127,000. Hedge funds and other institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Price Performance

AUTL stock traded down $0.06 during midday trading on Wednesday, hitting $3.45. 1,067,493 shares of the stock were exchanged, compared to its average volume of 1,398,069. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55. The stock has a market cap of $918.01 million, a price-to-earnings ratio of -2.87 and a beta of 2.05. Autolus Therapeutics plc has a fifty-two week low of $2.01 and a fifty-two week high of $7.45. The stock's 50-day moving average price is $4.03 and its 200-day moving average price is $4.35.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Research analysts predict that Autolus Therapeutics plc will post -0.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

AUTL has been the subject of several recent analyst reports. William Blair reissued an "outperform" rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. Needham & Company LLC restated a "buy" rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, June 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Autolus Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $8.70.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.